ADMA Biologics Inc (OQ:ADMA)

Business Focus: Bio Therapeutic Drugs

Oct 11, 2018 08:48 ET
ADMA Biologics Provides Regulatory Update for BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Oct 03, 2018 07:08 ET
ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency...
Oct 01, 2018 07:08 ET
ADMA Biologics Resubmits Biologics License Application for RI-002
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency...
Sep 05, 2018 07:08 ET
ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain...
Aug 27, 2018 07:28 ET
ADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ADMA Biologics, Inc. (NASDAQ: ADMA) (the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease...
Aug 10, 2018 07:08 ET
ADMA Biologics Reports Second Quarter 2018 Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”) today announced its financial results for the quarter ended June 30, 2018 and provided an update on its operations and corporate objectives. “During the quarter we strengthened our...
Jul 26, 2018 10:50 ET
ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain...
Jul 26, 2018 07:58 ET
ADMA Biologics Receives PDUFA Date for BIVIGAM® Regulatory Submission
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain...
Jun 25, 2018 07:08 ET
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes
ADMA Biologics, Inc. (NASDAQ:ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain infectious diseases, today...
Jun 12, 2018 16:05 ET
ADMA Biologics Announces Closing of $40M Public Offering
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share.  The gross...
Jun 08, 2018 09:08 ET
ADMA Biologics Announces Pricing of Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share, resulting in...
Jun 07, 2018 16:05 ET
ADMA Biologics Announces Proposed Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today that it has commenced an underwritten public offering of its common stock.  The Company intends to grant the underwriters of the offering a 30-day option to purchase up to...
May 16, 2018 07:30 ET
ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”) today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793 covering methods of treating respiratory infections. The newly issued...
May 14, 2018 17:05 ET
ADMA Biologics Reports First Quarter 2018 Financial Results
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), today announced its financial results for the quarter ended March 31, 2018 and provided an update on its operations and corporate objectives. “During the first quarter, we achieved...
May 14, 2018 13:17 ET
ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”) announced today that it has negotiated the receipt and immediate retirement of approximately 8.6 million shares of its non-voting common stock previously issued to Biotest Pharmaceuticals...
Apr 24, 2018 07:28 ET
ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership
Operational Leadership Team Executes on Production and Commercialization of the Company’s Immune Globulin Product for the Treatment of Hepatitis B Infection
Mar 05, 2018 07:00 ET
ADMA Biologics Reports Full Year 2017 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for...
Feb 27, 2018 07:08 ET
ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of...
Dec 11, 2017 07:08 ET
ADMA Files Biologics License Application For Its Third Plasma Collection Center
ADMA BioCenters’ Newest Facility Commences Operations to Further Supplement Supply of Internally-Sourced Donor Plasma for Commercial Products and Pipeline of Hyperimmune IG Candidates
Nov 15, 2017 08:08 ET
ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and commercializes plasma-based biologics for the treatment of immune deficiencies...
Nov 13, 2017 12:30 ET
ADMA Biologics Announces Closing of $42M Follow-On Offering
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets plasma-based biologics designed to...
Nov 09, 2017 08:58 ET
ADMA Biologics Announces Pricing of Follow-On Offering
RAMSEY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics designed to treat Primary Immune...
Nov 03, 2017 17:02 ET
ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
RAMSEY, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary...
Aug 11, 2017 16:15 ET
ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
RAMSEY, N.J., Aug. 11, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, today announced its financial results for the quarter ended June 30, 2017 and provided a corporate update....
Jul 31, 2017 16:15 ET
ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods
RAMSEY, N.J. and BOCA RATON, Fla., July 31, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin  company  that develops, manufactures and commercializes specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, announced today that the United States Patent and Trademark Office has issued to the Company U.S. Patent No. 9,714,283, which encompasses methods of providing immunotherapy to patients using immune globulin compositions proprietary t...
May 25, 2017 16:15 ET
ADMA Biologics to Present at Jefferies 2017 Healthcare Conference
RAMSEY, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced that Adam Grossman, President and CEO is scheduled to provide a corporate overview at the Jefferies 2017 Healthcare Conference on June 8, 2017 at 8:30 AM ET....
Mar 27, 2017 18:39 ET
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA
NEW YORK, March 27, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating  ADMA Biologics, Inc. ("ADMA" or the "Company")(NasdaqGS: ADMA)  and its Board of Directors for potential securities laws violations and/or breaches of fiduciary duties in connection with the Purchase Agreement with Biotest Pharmaceuticals Corporation for its therapy business (the "Purchase Agreement").  ...
Feb 24, 2017 16:37 ET
ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones
RAMSEY, N.J., Feb. 24, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2016....
Nov 10, 2016 16:30 ET
ADMA Biologics Reports Third Quarter 2016 Results
RAMSEY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended September 30, 2016....
Sep 01, 2016 07:38 ET
ADMA Biologics to Present at Upcoming Investor Conferences
RAMSEY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention and treatment of certain infectious diseases, announced today that Adam Grossman, President and CEO is scheduled to provide a corporate overview at the following two September investor conferences:...
Aug 12, 2016 16:38 ET
ADMA Biologics Reports Second Quarter 2016 Results
RAMSEY, N.J., Aug. 12, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended June 30, 2016....
Aug 01, 2016 16:31 ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ADMA Biologics, Inc. (ADMA)
NEW YORK, Aug. 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ADMA Biologics, Inc. ("ADMA" or the "Company") (Nasdaq: ADMA). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484....
Aug 01, 2016 15:47 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, Aug. 1, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jul 29, 2016 19:14 ET
ADMA Biologics Receives Complete Response Letter from FDA for Pending Biologics License Application
RAMSEY, N.J., July 29, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s Biologics License Application (BLA) for RI-002, an Intravenous Immune Globulin (IVIG), for the treatment of patients with Primary Humoral Immunodeficiency Disease (PI...
Jun 16, 2016 07:38 ET
ADMA Biologics to Present at the 2016 JMP Securities Life Sciences Conference
RAMSEY, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2016 JMP Securities Life Sciences Conference on June 21, 2016 at The St. Regis New York....
May 13, 2016 17:05 ET
ADMA Biologics Reports First Quarter 2016 Results
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the quarter ended March 31, 2016, and recent accomplishments and anticipated milestones for 2016....
May 13, 2016 16:05 ET
ADMA Biologics Further Enhances Cash Position by Securing $4.0 Million in Additional Capital Through Amended Loan and Security Agreement with Oxford Finance
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has accessed an additional $4.0 million from its lender, Oxford Finance LLC (Oxford), made available through an amendment of the parties' existing loan and security agreement.  The amendment provides ADMA with the option to draw an additional $5 million upon the approval for its Biologics Licen...
May 03, 2016 10:46 ET
ADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAMSEY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,892,308 shares of its common stock at a public offering price of $6.50 per share, as well as 283,846 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.  ...
Apr 28, 2016 09:15 ET
ADMA Biologics Announces Pricing of Public Offering of Common Stock
RAMSEY, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds of approximately $12.3 million. Members of management and the Board of Directors participated in excess of ten percent i...
Apr 27, 2016 16:05 ET
ADMA Biologics Announces Proposed Public Offering of Common Stock
RAMSEY, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering.  The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any.  The proposed offering is subject to market and other condi...